ARTICLE | Clinical News
Pharmadigm Phase II results
March 17, 2000 8:00 AM UTC
Pharmadigm (Salt Lake City, Utah) reported results of its Phase II trial of PB005, a synthetic injectable form of dehydroepiandrosterone sulfate (DHEAS), in 63 severely burned patients undergoing auto...